Gillian Grafton, DO
Advanced Heart Failure and Transplant Cardiology · Detroit, MINPI 1043475148
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,862 of the $8,065 with a category attached, or 60.3%. Abbott accounts for 73.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $3,260 and has fallen 86.5% since, to $442 in 2025.
Across 112 payments — averaging $72.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Abiomed$1K
- Procyrion, Inc.$220
- United Therapeutics Corporation$206
- Amgen$80
- Endotronix, Inc.$61
- plus $105 from 4 others
Across 79 payments — averaging $14,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$396K
- United Therapeutics Corporation$352K
- Abbott$254K
- Briohealth Solutions, Inc.$162K
What the payments were for
- Consulting fees$4886%
- Travel & lodging$2,71534%
- Food & beverage$4,86260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 87 | $5,963 |
| Abiomed | 10 | $1,430 |
| Procyrion, Inc. | 6 | $220 |
| United Therapeutics Corporation | 3 | $206 |
| Amgen | 1 | $80 |
| Endotronix, Inc. | 1 | $61 |
| Medtronic | 1 | $56 |
| Pfizer | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| EKOS Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,065 in reported general payments places this provider in the 65th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 102 | $1,380,919 |
| UptraviSelexipag | 59 | $1,275,195 |
| OpsumitMacitentan | 46 | $576,333 |
| Orenitram ErTreprostinil Diolamine | 26 | $231,675 |
| Ambrisentan | 36 | $120,949 |
| JardianceEmpagliflozin | 110 | $108,209 |
| EntrestoSacubitril/Valsartan | 80 | $77,567 |
| Tadalafil | 93 | $72,138 |
| FarxigaDapagliflozin Propanediol | 56 | $40,476 |
| EliquisApixaban | 50 | $40,020 |
| Praluent PenAlirocumab | 12 | $7,970 |
| Isosorbide Dinitrate | 14 | $5,617 |
| Sildenafil Citrate | 25 | $5,493 |
| Tacrolimus | 21 | $3,431 |
| Bumetanide | 55 | $2,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $40,02050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Detroit
- Jennifer CowgerDetroit$165K
- Waleed Al-DarziDetroit$11K
- Yelena SelektorDetroit$2K
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Thomas CascinoAnn Arbor$39K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Keith AaronsonAnn Arbor$22K
- Abbas BitarAnn Arbor$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.